Irosha Nawarathne

Dr. Irosha Nawarathne

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in ChemCatChem
Verified
Journal Article
Open access
AAAimen Al‐Hilfi
Aimen Al‐Hilfi
ZLZhen Li
Zhen Li
KMKenneth M. Merz
Kenneth M. Merz
INIrosha Nawarathne
Irosha Nawarathne
KWKevin D. Walker
Kevin D. Walker
A taxane 2‐O‐benzoyltransferase (mTBT, derived from Accession: AF297618) biocatalyzed the dearoylation and rearoylation of next‐generation taxane precursors of drugs effective against multidrug‐resistant cancer cells. Various taxanes bearing an acyl, hydroxyl, or oxo group at C13 were screened to assess their turnover by mTBT catalysis. The 13‐oxotaxanes were the most productive, where 2‐O‐debenzoylation of 13‐oxobaccatin III was turned over faster compared to 13‐oxo‐10‐O‐(n‐propanoyl)‐10‐O‐deacetylbaccatin III and 13‐oxo‐10‐O‐(cyclopropane carbonyl)‐10‐O‐deacetylbaccatin III, yielding ~20 mg of each. mTBT catalysis was likely affected by an intramolecular hydrogen bond with the C13−hydroxyl. Oxidation to the 13‐oxo recovered catalysis. The experimental data for the debenzoylation reaction was supported by Gaussian‐accelerated molecular dynamics simulations that evaluated the conformational changes caused by different functional groups at C13 of the substrate. These findings also helped postulate where the 2‐O‐benzoylation reaction occurs on the paclitaxel pathway in nature. mTBT rearoylated the debenzoylated 13‐oxobaccatin III acceptors fastest with a non‐natural 3‐fluorobenzoyl CoA among the other aroyl CoA thioesters evaluated, yielding ~10 mg of each with excellent regioselectivity at laboratory scale. Reducing the 13‐oxo group to a hydroxyl yielded key modified baccatin III precursors (~10 mg at laboratory scale) of new‐generation taxoids.

16 July 2019 in Journal of Chemical Education
Verified
Journal Article
Closed access
INIrosha Nawarathne
Irosha Nawarathne

3 August 2022 in Journal of the American Oil Chemists' Society
Verified
Journal Article
Closed access
MFMcKinley Fox
McKinley Fox
KNKaleb Newcomb
Kaleb Newcomb
COCassia Oliveira
Cassia Oliveira
ESEhsan Shakiba
Ehsan Shakiba
INIrosha Nawarathne
Irosha Nawarathne

8 March 2021 in MethodsX
Verified
Journal Article
Open access
AFAmanda Ford
Amanda Ford
LMLaShawna Miller
LaShawna Miller
JTJordan Trant
Jordan Trant
INIrosha Nawarathne
Irosha Nawarathne
Single-stranded circular oligonucleotides are heavily utilized in rolling circle amplification and rolling circle transcription technologies. Although various reported methodologies are available to synthesize circular, single-stranded DNA (ssDNA), the unduly complicated protocols and the associated cost minimize the utility of these methodologies to a non-expert or a beginner in the field. Our protocol provides the simplest yet robust synthesis of circular ssDNA templates to be utilized in various applications, using minimal resources. • In this manuscript, we describe the most basic approach to synthesize circular ssDNA. • Our method utilizes the minimal resources, yet it is robust. • The utility of the methodology is very high for a non-expert or a beginner in the field.

17 November 2022 in Journal of Chemical Education
Verified
Journal Article
Closed access
INIrosha Nawarathne
Irosha Nawarathne

3 March 2026 in Molecules
Verified
Journal Article
Open access
PDF file
LBLola Beeser
Lola Beeser
DADaniel Armstrong
Daniel Armstrong
MFMarissa S Fullerton
Marissa S Fullerton
IBIsabella Beasley
Isabella Beasley
WTWyatt Treadway
Wyatt Treadway
INIrosha Nawarathne
Irosha Nawarathne
Antimicrobial resistance (AMR) threatens global health, particularly through the rise of multidrug-resistant tuberculosis (MDR-TB) and other critical bacterial infections such as methicillin-resistant Staphylococcus aureus (MRSA). Rifamycins remain frontline antibiotics but are increasingly undermined by resistance. Here, we introduce a click-enabled platform for the synthesis of C8-functionalized rifamycins, which can be converted in a single additional step into efficacious 3′-hydroxy-5′-aminobenzoxazinorifamycins (bxRifs) and enzymatically into 25-deacetylated rifamycins (deAcRifs), providing access to novel antibacterial scaffolds that expand beyond the scope of traditional C8 modifications. Accordingly, we establish a modular strategy for late-stage analog development of the complex natural product rifamycin S, wherein azido and alkyne functionalities are installed via tailored core chemistry and converted into 1,2,3-triazoles through copper(I)-catalyzed click chemistry. Another key feature of this work is the development of systematic HPLC purification methods, enabling the isolation of analytically pure compounds despite structural complexity. The resulting analogs exhibit distinct antibacterial profiles, notably against Gram-positive bacteria including MRSA and Streptococcus mutans, informing structure–activity relationships and offering a foundation for further optimization. This approach supports the rapid diversification of rifamycin scaffolds to combat the escalating threat of AMR, while also establishing a foundation for future discovery through bioorthogonal applications.